Clinical Trials Logo

Clinical Trial Details — Status: Withdrawn

Administrative data

NCT number NCT04660045
Other study ID # 20-11022876
Secondary ID
Status Withdrawn
Phase Phase 2
First received
Last updated
Start date May 2022
Est. completion date June 2026

Study information

Verified date March 2022
Source Weill Medical College of Cornell University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study evaluates the effectiveness of acalabrutinib treatment in patients with chronic lymphocytic leukemia (CLL) deemed at high risk for Richter's Transformation (RT). This is a single arm study. Enrolled patients will initiate therapy with acalabrutinib and will dose continuously. While on study, subjects will be monitored monthly for the first 3 months, then every three months thereafter until disease progression, discontinuation due to toxicity, death, or study completion.


Description:

This is a multi-center, single arm, Phase II clinical trial to investigate the effectiveness of acalabrutinib treatment within 6 months of chronic lymphocytic leukemia (CLL) diagnosis for patients with CLL deemed at high risk for Richter's Transformation (RT).


Recruitment information / eligibility

Status Withdrawn
Enrollment 0
Est. completion date June 2026
Est. primary completion date January 2026
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Subject must be able to voluntarily sign and date an informed consent, approved by an Independent Ethics Committee (IEC)/Institutional Review Board (IRB), prior to the initiation of any screening or study specific procedures. - The time from diagnosis to consent should be =6 months. - Subject must be = 18 years of age. - Subject must have diagnosis of CLL/SLL based upon 2018 iwCLL Guidelines. - Rai stage 0-2 disease without indication for treatment as defined by the 2018 iwCLL guidelines - Subject must have high risk CLL as defined by any one of the following: - NOTCH1 mutated (classic frameshift mutation only) - Unmutated V4-39 B cell receptor usage - Pathogenic c-MYC mutations - Complex karyotype, (by CpG/oligodeoxynucleotide stimulation) - Deletion 17p, or presence of TP53 mutation - Subject has an Eastern Cooperative Oncology Group (ECOG) performance score of = 2. - PT/PTT/INR within 1.5 x the ULN - Adequate renal function defined by serum creatinine less than 2 x ULN - Adequate hepatic function: - ALT/AST less than 2x ULN - Tbili less than 1.5 X ULN unless bilirubin elevation is due to Gilbert's syndrome (total bilirubin <3) - Subject must have adequate bone marrow function. - Absolute neutrophil count =1.0 x103/µL - Hemoglobin = 11.0 g/dL - Platelets = 100 x 103/µL Exclusion Criteria: - Previous exposure to any systemic anti-cancer therapy as a treatment for CLL, including but not limited to chemotherapy, immunotherapy, radiotherapy, or investigational therapy. Note, patients treated with chemotherapy for a prior non-hematologic malignancy if more than 5 years earlier are eligible. - Subject with a history of malignancy except for non-melanoma skin cancers. Subjects treated with curative intent via methods of local resection and or locally targeted anticancer treatment and are free of malignancy for at least 5 years from treatment end will be allowed to enroll. - Subject requires chronic immunosuppressive therapy for any reason or was treated with immunosuppressive therapy within 6 months of study entry. - Subjects with a history of autoimmune hemolytic anemia or immune thrombocytopenia purpura. - Subject has prolymphocytic leukemia. - Active bleeding, or history of bleeding diathesis (e.g., hemophilia or von Willebrand disease) - Subject requires warfarin or equivalent vitamin K antagonist - Uncontrolled or active significant infection, - History of or suspected or confirmed PML - Clinically significant cardiovascular disease such as uncontrolled or symptomatic arrhythmias, congestive heart failure, or myocardial infarction within 6 months of screening, or any Class 3 or 4 cardiac disease as defined by the New York Heart Association Functional Classification. Subjects with controlled, asymptomatic atrial fibrillation during screening can enroll on study. - Patients with stroke or CNS hemorrhage within 6 months - Pregnant or breastfeeding - Women of childbearing potential (WCBP) who are sexually active with heterosexual partners must agree to use highly effective methods of contraception during treatment and for 2 days after the last dose of acalabrutinib. - Major surgical procedure within 28 days of first dose of study drug. If a subject had surgery, they must have recovered adequately from any toxicity or complications before the first dose of study drug. - Has difficulty with or is unable to swallow oral medication or has significant gastrointestinal disease that would limit absorption of oral medication. - Subject is known to be positive for human immunodeficiency virus (HIV) - Active hepatitis C, as confirmed by being positive for Hep C RNA by PCR - Active hepatitis B infection documented by a positive PCR for Hep B DNA. If hepatitis B serology is positive for hepatitis B core antibody, but Hep B DNA PCR is negative, patient is eligible to enroll. - Subject requires strong CYP 3A4/5 inhibitors or inducers (Appendix B). - Subject requires proton pump inhibitors. (Subjects that can transition to an H2 antagonist are allowed to enroll.)

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Acalabrutinib
Acalabrutinib, oral, 100 mg BID, continuous

Locations

Country Name City State
United States Weill Cornell Medicine New York New York

Sponsors (2)

Lead Sponsor Collaborator
Weill Medical College of Cornell University AstraZeneca

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Percentage of subjects who do not develop Richter's Transformation (RT) within 5 years of study drug administration 5 years
Secondary Event-free survival Measured from time of study drug administration to time of progression, transformation to a more aggressive histology, treatment discontinuation due to toxicity, or death from any cause. 5 years
Secondary Progression-free survival Measured from time of study drug administration to progression or death, measured in months. 5 years
Secondary Progression-free survival in patients with TP53 disruption For subjects with TP53 disruption present at baseline, measured from time of study drug administration to progression or death, measured in months. 5 years
Secondary Overall survival Measured from time of study drug administration to death from any cause, measured in months. 5 years
Secondary Percentage of subjects who do not develop Richter's Transformation within 2 years of study drug administration 2 years
Secondary Median time to development of RT Measured from time of study drug administration 5 years
Secondary Safety of early interventional acalabrutinib in patients with chronic lymphocytic leukemia (CLL) at high risk for Richter's Transformation Percentage of subjects who experience 1 or more adverse events. 5 years
See also
  Status Clinical Trial Phase
Recruiting NCT05400122 - Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer Phase 1
Enrolling by invitation NCT01804686 - A Long-term Extension Study of PCI-32765 (Ibrutinib) Phase 3
Completed NCT02057185 - Occupational Status and Hematological Disease
Active, not recruiting NCT04240704 - Safety and Preliminary Efficacy of JBH492 Monotherapy in Patients With CLL and NHL Phase 1
Recruiting NCT03676504 - Treatment of Patients With Relapsed or Refractory CD19+ Lymphoid Disease With T Cells Expressing a Third-generation CAR Phase 1/Phase 2
Active, not recruiting NCT03280160 - Protocol GELLC-7: Ibrutinib Followed by Ibrutinib Consolidation in Combination With Ofatumumab Phase 2
Active, not recruiting NCT03844048 - An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial Phase 3
Completed NCT00038025 - A Study Of Deoxycoformycin(DCF)/Pentostatin In Lymphoid Malignancies Phase 2
Recruiting NCT04904588 - HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide Phase 2
Terminated NCT02231853 - Phase I/II Trial of Early Infusion of Rapidly-generated Multivirus Specific T Cells (MVST) to Prevent Post Transplant Viral Infections Phase 1
Recruiting NCT05417165 - Anti-pneumococcal Vaccine Strategy in Patients With Chronic Lymphocytic Leukemia Phase 2
Recruiting NCT04028531 - Understanding Chronic Lymphocytic Leukemia
Completed NCT00001637 - Immunosuppressive Preparation Followed by Blood Cell Transplant for the Treatment of Blood Cancers in Older Adults Phase 2
Completed NCT02910583 - Ibrutinib Plus Venetoclax in Subjects With Treatment-naive Chronic Lymphocytic Leukemia /Small Lymphocytic Lymphoma (CLL/SLL) Phase 2
Completed NCT01527045 - Donor Atorvastatin Treatment in Preventing Severe Acute GVHD After Nonmyeloablative Peripheral Blood Stem Cell Transplant in Patients With Hematological Malignancies Phase 2
Recruiting NCT04679012 - Polatuzumab Vedotin in Combination With Chemotherapy in Subjects With Richter's Transformation Phase 2
Recruiting NCT05405309 - RP-3500 and Olaparib in DNA Damage Repair Pathway Deficient Relapsed/Refractory Chronic Lymphocytic Leukemia Phase 1/Phase 2
Active, not recruiting NCT05023980 - A Study of Pirtobrutinib (LOXO-305) Versus Bendamustine Plus Rituximab (BR) in Untreated Patients With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) Phase 3
Recruiting NCT04553692 - Phase 1a/1b Study of Aplitabart (IGM-8444) Alone or in Combination in Participants With Relapsed, Refractory, or Newly Diagnosed Cancers Phase 1
Completed NCT04666025 - SARS-CoV-2 Donor-Recipient Immunity Transfer